Pasquiers B, Benamara S, Felices M, Nguyen L, Decleves X
Int J Mol Sci. 2022; 23(21).
PMID: 36361546
PMC: 9657028.
DOI: 10.3390/ijms232112754.
Wang H, Xu Q, Zhao C, Zhu Z, Zhu X, Zhou J
J Immunother Cancer. 2020; 8(2).
PMID: 32819973
PMC: 7443307.
DOI: 10.1136/jitc-2020-000661.
Kang T, Jung S
Biomolecules. 2020; 10(3).
PMID: 32121592
PMC: 7175108.
DOI: 10.3390/biom10030382.
Zhang L, Li W, Sun Y, Kong L, Xu P, Xia P
Viruses. 2020; 12(2).
PMID: 32046249
PMC: 7077232.
DOI: 10.3390/v12020187.
Kang T, Jung S
Exp Mol Med. 2019; 51(11):1-9.
PMID: 31735912
PMC: 6859160.
DOI: 10.1038/s12276-019-0345-9.
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
Liefferinckx C, Verstockt B, Gils A, Tops S, van Moerkercke W, Vermeire S
United European Gastroenterol J. 2019; 7(6):750-758.
PMID: 31316779
PMC: 6620879.
DOI: 10.1177/2050640619841538.
The genomic organization and expression pattern of the low-affinity Fc gamma receptors (FcγR) in the Göttingen minipig.
Egli J, Schmucki R, Loos B, Reichl S, Grabole N, Roller A
Immunogenetics. 2018; 71(2):123-136.
PMID: 30564855
PMC: 6327001.
DOI: 10.1007/s00251-018-01099-1.
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.
Derijks L, Wong D, Hommes D, van Bodegraven A
Clin Pharmacokinet. 2018; 57(9):1075-1106.
PMID: 29512050
DOI: 10.1007/s40262-018-0639-4.
Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.
Morotti M, Hari Dass P, Harris A, Lord S
Eur J Drug Metab Pharmacokinet. 2017; 43(2):137-153.
PMID: 29019020
DOI: 10.1007/s13318-017-0442-x.
Comprehensive Characterization of Relationship Between Higher-Order Structure and FcRn Binding Affinity of Stress-Exposed Monoclonal Antibodies.
Tsuchida D, Yamazaki K, Akashi S
Pharm Res. 2015; 33(4):994-1002.
PMID: 26694753
DOI: 10.1007/s11095-015-1845-5.
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
Majumdar R, Esfandiary R, Bishop S, Samra H, Middaugh C, Volkin D
MAbs. 2014; 7(1):84-95.
PMID: 25524268
PMC: 4623389.
DOI: 10.4161/19420862.2014.985494.
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.
Veillette M, Coutu M, Richard J, Batraville L, Dagher O, Bernard N
J Virol. 2014; 89(1):545-51.
PMID: 25339767
PMC: 4301108.
DOI: 10.1128/JVI.02868-14.
Functional Fcgamma receptor polymorphisms are associated with human allergy.
Wu J, Lin R, Huang J, Guan W, Oetting W, Sriramarao P
PLoS One. 2014; 9(2):e89196.
PMID: 24586589
PMC: 3931680.
DOI: 10.1371/journal.pone.0089196.
Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K
MAbs. 2013; 5(2):237-54.
PMID: 23392215
PMC: 3893234.
DOI: 10.4161/mabs.23363.
Hydrodynamic delivery of plasmid DNA encoding human FcγR-Ig dimers blocks immune-complex mediated inflammation in mice.
Shashidharamurthy R, Machiah D, Bozeman E, Srivatsan S, Patel J, Cho A
Gene Ther. 2011; 19(9):877-85.
PMID: 22113315
PMC: 3296821.
DOI: 10.1038/gt.2011.175.
The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population.
Levy D, Bellesso M, Oliveira-Souza P, Maciel F, Pereira J, Bydlowski S
Clinics (Sao Paulo). 2011; 66(5):919-22.
PMID: 21789402
PMC: 3109397.
DOI: 10.1590/s1807-59322011000500034.
Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
Fitzgerald J, Lugovskoy A
MAbs. 2011; 3(3):299-309.
PMID: 21393992
PMC: 3149710.
DOI: 10.4161/mabs.3.3.15299.
Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.
Cohen-Solal J, Cassard L, Fournier E, Loncar S, Fridman W, Sautes-Fridman C
Dermatol Res Pract. 2010; 2010:657406.
PMID: 20672001
PMC: 2905727.
DOI: 10.1155/2010/657406.
Platelet-bacterial interactions.
Kerrigan S, Cox D
Cell Mol Life Sci. 2010; 67(4):513-23.
PMID: 20091082
PMC: 11115587.
DOI: 10.1007/s00018-009-0207-z.
Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
Jung S, Reddy S, Kang T, Jack Borrok M, Sandlie I, Tucker P
Proc Natl Acad Sci U S A. 2010; 107(2):604-9.
PMID: 20080725
PMC: 2818909.
DOI: 10.1073/pnas.0908590107.
